Reata Pharmaceuticals Stock Forecast, Price & News

Reata Pharmaceuticals (NASDAQ:RETA) Frequently Asked Questions

Is Reata Pharmaceuticals a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Reata Pharmaceuticals stock.
View analyst ratings for Reata Pharmaceuticals or view top-rated stocks.

How has Reata Pharmaceuticals' stock been impacted by Coronavirus?

Reata Pharmaceuticals' stock was trading at $157.86 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, RETA stock has decreased by 82.7% and is now trading at $27.26.
View which stocks have been most impacted by COVID-19.

When is Reata Pharmaceuticals' next earnings date?

Reata Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Reata Pharmaceuticals.

How were Reata Pharmaceuticals' earnings last quarter?

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) announced its quarterly earnings results on Monday, November, 8th. The company reported ($1.97) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($2.32) by $0.35. The business earned $7.40 million during the quarter, compared to the consensus estimate of $2.07 million. Reata Pharmaceuticals had a negative net margin of 2,020.49% and a negative trailing twelve-month return on equity of 81.91%. Reata Pharmaceuticals's quarterly revenue was up 428.6% on a year-over-year basis. During the same period in the previous year, the business posted ($1.94) earnings per share.
View Reata Pharmaceuticals' earnings history.

What price target have analysts set for RETA?

6 Wall Street analysts have issued 12 month target prices for Reata Pharmaceuticals' shares. Their forecasts range from $35.00 to $244.00. On average, they expect Reata Pharmaceuticals' stock price to reach $85.00 in the next year. This suggests a possible upside of 211.8% from the stock's current price.
View analysts' price targets for Reata Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Reata Pharmaceuticals' key executives?

Reata Pharmaceuticals' management team includes the following people:

• J. Warren Huff, Chairman, President & Chief Executive Officer
• Manmeet Singh Soni, Executive VP, Chief Operating & Financial Officer
• W. Christian Wigley, Chief Scientific Officer, SVP & Founding Scientist
• Colin J. Meyer, Chief Research & Development Officer, Executive VP (LinkedIn Profile)
• Edmund Doherty, Vice President-Medical Affairs

What is Warren Huff's approval rating as Reata Pharmaceuticals' CEO?

10 employees have rated Reata Pharmaceuticals CEO Warren Huff on Glassdoor.com. Warren Huff has an approval rating of 92% among Reata Pharmaceuticals' employees. This puts Warren Huff in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Reata Pharmaceuticals' key competitors?

Some companies that are related to Reata Pharmaceuticals include Alkermes (ALKS), Cerevel Therapeutics (CERE), Galapagos (GLPG), Arvinas (ARVN), ACADIA Pharmaceuticals (ACAD), Hypera (HYPMY), Karuna Therapeutics (KRTX), Apellis Pharmaceuticals (APLS), Intra-Cellular Therapies (ITCI), Dicerna Pharmaceuticals (DRNA), OPKO Health (OPK), Pacira BioSciences (PCRX), PTC Therapeutics (PTCT), Prestige Consumer Healthcare (PBH) and Zentalis Pharmaceuticals (ZNTL).
View all of RETA's competitors.

What other stocks do shareholders of Reata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Synlogic (SYBX), NVIDIA (NVDA), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO) and Archrock (AROC).

When did Reata Pharmaceuticals IPO?

(RETA) raised $60 million in an IPO on Thursday, May 26th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray served as the underwriters for the IPO.

What is Reata Pharmaceuticals' stock symbol?

Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."

Who are Reata Pharmaceuticals' major shareholders?

Reata Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include MADDEN SECURITIES Corp (0.11%), Cutler Group LP (0.00%) and Woodstock Corp (0.04%). Company insiders that own Reata Pharmaceuticals stock include Colin John Meyer, Elaine Castellanos, James Warren Huff and Michael D Wortley.
View institutional ownership trends for Reata Pharmaceuticals.

Which institutional investors are selling Reata Pharmaceuticals stock?

RETA stock was sold by a variety of institutional investors in the last quarter, including Woodstock Corp. Company insiders that have sold Reata Pharmaceuticals company stock in the last year include Colin John Meyer, and Elaine Castellanos.
View insider buying and selling activity for Reata Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Reata Pharmaceuticals stock?

RETA stock was purchased by a variety of institutional investors in the last quarter, including Cutler Group LP, and MADDEN SECURITIES Corp.
View insider buying and selling activity for Reata Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Reata Pharmaceuticals?

Shares of RETA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Reata Pharmaceuticals' stock price today?

One share of RETA stock can currently be purchased for approximately $27.26.

How much money does Reata Pharmaceuticals make?

Reata Pharmaceuticals has a market capitalization of $992.05 million and generates $9.02 million in revenue each year. The company earns $-247.75 million in net income (profit) each year or ($7.73) on an earnings per share basis.

How many employees does Reata Pharmaceuticals have?

Reata Pharmaceuticals employs 267 workers across the globe.

What is Reata Pharmaceuticals' official website?

The official website for Reata Pharmaceuticals is www.reatapharma.com.

Where are Reata Pharmaceuticals' headquarters?

Reata Pharmaceuticals is headquartered at 5320 LEGACY DRIVE, PLANO TX, 75024.

How can I contact Reata Pharmaceuticals?

Reata Pharmaceuticals' mailing address is 5320 LEGACY DRIVE, PLANO TX, 75024. The company can be reached via phone at (972) 865-2219 or via email at [email protected].